NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 365 filers reported holding NEKTAR THERAPEUTICS in Q1 2018. The put-call ratio across all filers is 0.43 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $578,000 | +125.8% | 16,234 | +113.3% | 0.02% | 0.0% |
| Q1 2019 | $256,000 | +3.6% | 7,612 | +1.1% | 0.02% | -7.4% |
| Q4 2018 | $247,000 | -44.9% | 7,529 | +2.5% | 0.03% | -37.2% |
| Q3 2018 | $448,000 | +34.1% | 7,345 | +7.4% | 0.04% | +26.5% |
| Q2 2018 | $334,000 | -62.6% | 6,841 | -18.5% | 0.03% | -55.3% |
| Q1 2018 | $892,000 | – | 8,398 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,000,000 | $69,480,000 | 3.98% |
| MAVERICK CAPITAL LTD | 5,186,637 | $120,123,000 | 2.53% |
| Rhenman & Partners Asset Management AB | 790,000 | $18,296,000 | 1.98% |
| Goodman Financial Corp | 121,439 | $2,813,000 | 1.41% |
| Bellevue Group AG | 3,535,013 | $81,871,000 | 1.16% |
| Gs Investments, Inc. | 54,200 | $1,255,272,000 | 1.00% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 493,586 | $11,431,000 | 0.83% |
| RICE HALL JAMES & ASSOCIATES, LLC | 565,833 | $13,105,000 | 0.56% |
| DCF Advisers, LLC | 43,000 | $996,000 | 0.56% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,499,000 | 0.50% |